Matinas BioPharma
MTNB
24 hedge funds and large institutions have $177K invested in Matinas BioPharma in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
1.38% less ownership
Funds ownership: 6.91% → 5.53% (-1.4%)
14% less funds holding
Funds holding: 28 → 24 (-4)
24% less capital inflows, than outflows
Capital inflows: $45.5K | Capital outflows: $60K
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.76K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$2.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$27.2K |
| 2 |
Jane Street
New York
|
-$9.32K |
| 3 |
VF
Virtu Financial
New York
|
-$9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.78K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.25K |
MTNB Hedge Fund Activity: Q1 2026 in Review
24 of the 8,210 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2026, worth a combined $177K — down 32% from $260K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MTNB and 3 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $5.76K. The largest seller was DRW Securities, exiting entirely with an estimated $27.2K sold.
- 24 institutional investors held Matinas BioPharma (MTNB) as of Q1 2026, down from 28 in Q4 2025.
- Funds reported $177K of Matinas BioPharma stock for Q1 2026, down 32% quarter-over-quarter.
- 3 funds opened new Matinas BioPharma positions in Q1 2026 and 6 closed out, a net change of -3 holders.
- The largest Matinas BioPharma buyer in Q1 2026 was Geode Capital Management, an estimated $5.76K added.
- The largest Matinas BioPharma seller in Q1 2026 was DRW Securities, an estimated $27.2K sold.
Based on aggregated 13F filings for Q1 2026.